Skip to content

Pain in Cancer Survivors

Pain in Cancer Survivors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00581724
Enrollment
200
Registered
2007-12-28
Start date
2007-05-31
Completion date
2012-01-31
Last updated
2012-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer

Keywords

breast cancer, Colorectal cancer, Prostate cancer, Head and Neck cancer, Lung cancer, cancer survivors, 07-068, quality of life, Pain in cancer survivors

Brief summary

The purpose of this study is to find out about the pain and quality of life of individuals who are adult cancer survivors. By quality of life, we mean how you are feeling about different aspects of your life, including your physical health, your emotional health, and your ability to carry out daily activities. We are interested in people's opinions about their quality of life, as well as the factors that affect their quality of life. In addition, learning about pain will help us to develop new services for adult cancer survivors.

Detailed description

The main objective of the proposed study is to identify the prevalence of persistent pain in a sample of adult cancer survivors. Currently, there is a lack of comprehensive information about pain in the cancer survivor population. Although prior studies have assessed pain syndromes in breast and lung cancer survivors (e.g., post-mastectomy and post-thoracotomy pain), there is a lack of information about the prevalence and characteristics of post-treatment pain in other subpopulations of survivors. To address this knowledge gap, a random sample of cancer survivors who are from 1 to 10 years post-treatment completion and who were treated at Memorial Sloan-Kettering Cancer Center will complete a telephone-administered pain interview and assessment battery focusing on pain, quality of life, and psychological distress. Our initial recruitment and evaluation will begin in 50 breast cancer survivors and then will expand 50 survivors in each of the other services Colorectal, Genitourinary, Head and Neck, and Thoracic in allotments of 50 participants each. We estimate that the completion time for the interview and assessment battery will range from 45 to 60 minutes. This telephone-based survey will identify vulnerable subgroups of patients with persistent pain and provide a knowledge base for future research on the prevalence and risk factors for post-treatment pain in the cancer survivor population.

Interventions

BEHAVIORALTelephone interview or self report survey.

We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.

Sponsors

Beth Israel Medical Center
CollaboratorOTHER
Vanderbilt University
CollaboratorOTHER
Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cancer treatment at MSKCC * Are from 1 to 10 years post-treatment completion at the time of study recruitment * No evidence of disease (NED) at the time of assessment; * Over 18 years of age * Can be reached by telephone * Able to provide informed consent * Able to speak and read English * Cancer survivors who received adjuvant therapies outside MSKCC will be asked to self-report the type and duration of cancer treatments received.

Exclusion criteria

* Undergoing active cancer treatment (ongoing tamoxifen use, hormone replacement therapy or use of biologics are permitted) * Evidence of encephalopathy, psychotic illness or cognitive impairment severe enough to preclude giving informed consent to the study staff, or completing the survey instruments of the study.

Design outcomes

Primary

MeasureTime frame
Descriptive statistics will be generated to describe the prevalence of pain and its psychosocial correlates.1 to 10 years post-treatment completion

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026